Commvault Systems Inc vs Zoetis Inc — how do they compare? Commvault Systems Inc trades at $156.75 (market cap $6.25B), while Zoetis Inc trades at $74.56 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.8× Commvault Systems Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Zoetis Inc for 70 Days on average.
| CVLT | ZTS | |
|---|---|---|
Market Cap | $6.25B | $30.20B |
Volume | 632,727 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $176.52 | $147.53 |
52-Week Low | $75.18 | $69.09 |
Typical Hold Time | 17 Days | 70 Days |
Enterprise Value | $6.24B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $155.16, up 3.25% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.42 exceeding expectations, though valuation metrics remain elevated with a P/E of 96.73. Recent positive developments include AWS Data Competency achievement and expanded FedRAMP authorization, supporting the company's AI-focused resilience platform.
CVLT presents growth potential through its AI integration and cloud partnerships, but faces risks from high valuation multiples and declining profit margins. With 54.55% analyst buy ratings and a $156.55 consensus target, the stock appears fairly valued near current levels, requiring careful monitoring of execution against growth expectations.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Trailing returns across standard periods
Latest headlines on both assets
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →